Entia develops patented, pharmaceutical grade organic compounds, including one known as ErgoD . Entia believes that ErgoD improves iron homeostasis and mitigates iron related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. Entia s goal is to clinically validate and commercialize ErgoD through the prescription Medical Food and OTC Supplement channels.
Quote | Entia Biosciences Inc (OTCMKTS:ERGO)
Last: | $0.0001 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0001 |
Close: | $0.0001 |
High: | $0.0001 |
Low: | $0.0001 |
Volume: | 6,000 |
Last Trade Date Time: | 03/25/2024 03:00:00 am |
News | Entia Biosciences Inc (OTCMKTS:ERGO)
PRESS RELEASE Ergomed strongly positioned for future growth in new partnership with Permira Permira completes acquisition of Ergomed for £703.1 million Through this partnership, Permira will support Dr. Miroslav Reljanović and the team in Ergomed’...
(NewsDirect) Jonathan Curtain, the new CFO of Ergomed, discussed his background and the company's growth prospects in an interview with Proactive London. The specialist services provider to the pharmaceutical industry focuses on growth areas like rare diseases and oncology. Curtain brings...
Message Board Posts | Entia Biosciences Inc (OTCMKTS:ERGO)
Subject | By | Source | When |
---|---|---|---|
is this one coming back to life? | dazetrader | investorshub | 12/09/2022 5:25:09 AM |
I never said new. It's old management. | Market Makers Exist | investorshub | 03/10/2022 5:07:16 PM |
Who are the new officers by the way? | dazetrader | investorshub | 03/10/2022 5:06:25 PM |
I am just more selective on OTC plays | Golden Cross | investorshub | 03/10/2022 4:48:40 PM |
Are you moving away from OTC/PINK and onto NYSE/Nasdaq/AMEX? | dazetrader | investorshub | 03/10/2022 4:45:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Entia Biosciences Inc Company Name:
ERGO Stock Symbol:
OTCMKTS Market:
Entia Biosciences Inc Website:
PRESS RELEASE Ergomed strongly positioned for future growth in new partnership with Permira Permira completes acquisition of Ergomed for £703.1 million Through this partnership, Permira will support Dr. Miroslav Reljanović and the team in Ergomed’...
(NewsDirect) Jonathan Curtain, the new CFO of Ergomed, discussed his background and the company's growth prospects in an interview with Proactive London. The specialist services provider to the pharmaceutical industry focuses on growth areas like rare diseases and oncology. Curtain brings...
PRESS RELEASE Ergomed expands operations in Japan N ew legal entity and regional office established in Tokyo respond ing to client demand Guildford , UK – 26 April ...